|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | DIRECT CORONAPY ANGIOPLASTY FOR ACUTE MYOCARDIAL INFARCTION:A SINGLE CENTRE EXPERIENCE显示文摘 | S.Kar E.Manolas P.Kumar R.Dick Y Lim M.Rowe | 1996 | 广东医学1996，17，S1： | 0 |
| 2 | 急性心肌梗塞的直接冠状动脉成形术:单中心经验显示文摘 | 张斌 S.Kar E.Manolas P.Kumar R.DIck 林廷龄 M.Rowe | 1996 | 广东医学1996，17，S1： | 0 |
| 3 | 冠状动脉内支架植入术321例分析显示文摘目的:评价冠状动脉内支架的临床价值。材料与方法:321例冠心病患者冠状动脉内植入451个支架,植入成功率97.8/,其中79.1%(254例)为B2型以上复杂性病变,因DeNovo及Suboptimal病变植入的支架占56.7%(182/321),Bail-out病变16.5%(53/321),再狭窄病变26.8%(86/321)。结果:28例曾行冠状动脉搭桥水患者的28文静脉移植血管(SVG)内植入49个支架,16例急性心肌梗塞患者接受原发支架植入。多支架植入99例,其中植入3个以上支架者26例。支架类型:Palmaz-schatz支架占69.7%(314个),NIR支架占20.6%(93个),其它支架占9.8%(44个)。多数病例使用高压球囊扩张,住院期间发生急性支架血栓形成6例(1.9%),亚急性支架血栓形成2例,其中1例因心肌梗塞死亡,无严重出血并发症。21例(6.5%)术后2-11个月胸痛复发者支架部位再狭窄,再次PTCA。结论:冠脉内支架是一种安全有效的介入性治疗技术.其扩大了PTCA的适应症,成功率高,并发症低,并减少再狭窄的发生。 | 万海燕 Y.L.LIM R.DICK M.ROWE | 1997 | 医学影像学杂志1997，7，2： | 0 |
| 4 | Inhibition of FLT3:A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia显示文摘Modern therapy of acute myeloid leukemia(AML)began in 1973 with the first report of the successful combination of daunorubicin and cytarabine,which led to complete remission in approximately 45%of patients.Accurate AML diagnosis was dependent on morphology,aided initially only by cytochemistry.Unlike acute lymphoblastic leukemia(ALL),immunophenotyping offered little in the diagnosis of AML,at least during the 1970s and 1980s.The advent of reliable cytogenetics changed the entire prognostic outlook of AML.With karyotypic analysis,different groups of AML could be classified and stratified for various therapies.Unique mutational profiling was a major advance in further categorizing AML patients,aided by the immunophenotypic identification of antigenic markers on the cells.All these advances were occurring as the understanding of the importance of the tumor burden—known as minimal residual disease(MRD)—became crucial for the management of AML patients.The efficacy of MRD has rapidly progressed in the past decade,from a specificity of 103 with immunophenotyping to 104 with polymerase chain reaction(PCR),which is only appropriate for some patients with AML,and finally to 105 or even 106 cells with the extraordinary sensitivity of next-generation sequencing(NGS).All of these advances have promoted the concept of personalized medicine,which has led to the advent of targeted agents that can accurately be used for specific diagnostic subtypes.Responses can be predicted and measured accurately.Such targeted agents have now become a cornerstone in the management of AML,increasing effi-cacy and dramatically reducing toxicity.The focus of this review is on one of the most well-studied targeted agents in AML:the FMS-like tyrosine kinase 3(FLT3)inhibitors,which have impacted the prognostication and therapeutics of AML.This review selectively discusses the FLT3 inhibitors in detail,as a model for the other burgeoning targeted agents that have already been approved,as well as those that are currently in development. | Meira Yisraeli Salman Jacob M.Rowe Nir Weigert | 2021 | Engineering2021，7，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员